GALECTIN THERAPEUTICS INC (GALT)
Health Care · Clinical-stage anti-fibrotic / liver disease therapeutics · NASDAQ
Clinical-stage biopharmaceutical company developing galectin-3 inhibitors derived from plant carbohydrates to treat liver fibrosis, cirrhosis, and cancer.
What GALECTIN THERAPEUTICS INC does
Galectin Therapeutics is a clinical-stage biopharmaceutical company developing therapies based on galectin protein inhibition, primarily targeting fibrotic disease and cancer. The company's lead candidate, belapectin (GR-MD-02), is a carbohydrate-based galectin-3 inhibitor derived from naturally occurring plant products, currently in clinical trials for metabolic dysfunction-associated steatohepatitis (MASH) with advanced fibrosis and cirrhosis.
Themes: ["Galectin-3 inhibition / fibrosis","MASH / liver cirrhosis","Anti-fibrotic therapeutics","Portal hypertension / esophageal varices prevention"]
Fundamentals
- Price$4.37 as of 2026-07-09 close
- Market cap$297M as of 2026-07-10
- 1-year return+94.2% as of 2026-07-09 close
- ROE-258.6% as of 2026-07-10
- Debt / equity11.09 as of 2026-07-10
- Beta0.34 as of 2026-07-10
Key risks (from latest filing)
["Belapectin did not meet statistical significance in the ITT population of the NAVIGATE Phase 2b/3 trial, though showed efficacy in the per-protocol population and U.S. subgroup; regulatory approval uncertain","Company has significant debt ($135.7M in convertible notes and credit facilities) with minimal revenue, burning ~$4M quarterly in operating losses, and only ~$14M cash on hand as of Q1 2026","Stockholders' deficit of $132M and accumulated deficit of $438M; dependent on financing and partnerships to continue clinical development and fund operations"]
Competitors & peers
- Intercept Pharmaceuticals
- Viking Therapeutics
- Rgenix
- Madrigal Pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.